Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.

Date publication

mai 2019

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier , Pr DELMER Alain

Tous les auteurs :
Manson G, Mear JB, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Garnier G, Regny C, Bouabdallah K, Moles-Moreau MP, Ghesquieres H, Tempescul A, Dulery R, Nicolas-Virelizier E, Delmer A, Borel C, Chauchet A, Damotte D, Dercle L, Brice P, Houot R,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31082693

Résumé

Long-term efficacy of anti-PD1 therapy and the need for a consolidation with allogenic haematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL).

Mots clés

Allogenic haematopoietic stem cell transplantation, Anti-PD1, Checkpoint inhibitors, Hodgkin lymphoma, Immunotherapy, Nivolumab

Référence

Eur. J. Cancer. 2019 May 10;115:47-56